FDA approves perioperative durvalumab plus enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; bladder robot gets De Novo nod

A clear specimen cup of pale liquid with a test strip leaning in it and its screw lid set beside it.

The Food and Drug Administration (FDA) approved durvalumab with enfortumab vedotin-ejfv around radical cystectomy on Nov. 13 for cisplatin-ineligible muscle invasive bladder cancer, based on the VOLGA trial. The American Cancer Society (ACS) now recommends regular PSA-based screening, Virtuoso Surgical announced FDA De Novo authorization for its endoscopic robot for bladder tumor resection, and a two-model AI consensus abstracted prostatectomy registry data with fewer errors than humans.

  • FDA Nov 13, 2026
    The Food and Drug Administration (FDA) approved durvalumab (Imfinzi) with enfortumab vedotin-ejfv before radical cystectomy, followed by durvalumab alone after surgery, for adults with muscle invasive bladder cancer who are ineligible for or refused cisplatin-based chemotherapy. The VOLGA trial randomized 695 patients 1:1:1, including to cystectomy alone. Median event-free survival was not reached with the combination versus 12.1 months with cystectomy alone (hazard ratio 0.51, 95% CI 0.38 to 0.67), and overall survival also favored the combination (hazard ratio 0.58, 95% CI 0.40 to 0.83), with medians not reached in either arm.
    Source: FDA
  • Guidelines Nov 12, 2026
    The American Cancer Society (ACS) guideline in CA: A Cancer Journal for Clinicians recommends PSA-based screening every two years for average-risk men aged 50 to 69 and yearly from 45 to 69 for Black men and men with a strong family history. Men with a PSA of 3.0 ng/mL or higher (6.5 ng/mL or higher at 70 to 74) should have repeat testing within two weeks to three months, and a confirmed elevated PSA should prompt an offer of MRI or a validated biomarker. The ACS said its 2010 guideline made no direct recommendation for regular screening.
  • FDA Nov 10, 2026
    Virtuoso Surgical announced Nov. 10 that the Food and Drug Administration (FDA) granted De Novo authorization on Oct. 30 to the Virtuoso Endoscopy System for urologic surgery in the bladder when a transurethral approach is appropriate, according to Urology Times. Two robotic arms at the tip of an endoscope work through the urethra, and the company said it is the first device in a new FDA classification for electromechanical surgical systems for endoluminal procedures. In company-reported data from the first 20 patients of the VIABLE study, detrusor muscle was present in 94% of removed lesions, with no intraoperative adverse events.
  • FDA Nov 12, 2026
    Clarity Pharmaceuticals said the Food and Drug Administration (FDA) granted 64Cu-SAR-bisPSMA breakthrough therapy designation for PET of PSMA-positive lesions in men with suspected prostate cancer recurrence based on elevated PSA, which the company called the first such designation in PSMA PET imaging. In the investigator-initiated Co-PSMA study cited by the company, 78% (39/50) of participants were positive on next-day 64Cu-SAR-bisPSMA PET/CT versus 36% (18/50) on 68Ga-PSMA-11 PET/CT. Topline data from the pivotal AMPLIFY and CLARIFY trials are expected in the first half of 2027, the company said.
  • AI Nov 11, 2026
    A Journal of Urology study used a consensus vote across two independent large language models to abstract surgical pathology and prostate MRI report data from 3,210 and 4,739 patients who had radical prostatectomy from 2010 to 2022. Median error rate on pathology data was 0.09% for the models versus 2.81% for human abstraction, and 0.17% versus 1.01% on MRI reports. Human abstraction of all 136,510 data elements was estimated at 952 hours.

The weekly innovation roundup for urology, published every Sunday for the week before; every item links to its sources. Latest urology news · All specialties

Latest news

Tagged urology, from the daily briefing

  1. American Cancer Society now recommends PSA screening every 2 years from 50 to 69, ending its 2010 shared-decision stance
  2. FDA approves durvalumab plus enfortumab vedotin around cystectomy for cisplatin-ineligible bladder cancer
  3. FDA opens a new device class with a robot that removes bladder tumors in one piece through the urethra

See all the latest news